French Cellectis purchases US electroporation specialist
Paris – French genome engineering specialist Cellectis SA has purchased all assets of Cyto Pulse Sciences Inc., for US$2m in cash. Celectis’ CEO André Choulika said the acquisition of US-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment "is a perfect strategic fit". Electroporation is very efficient to introduce Cellectis’ meganucleases into any type of cells, with applications ranging from research and bioproduction to agriculture and therapeutics.Pulse’s electrofusion technology is licensed broadly to antibody companies. In 2009 the US company had a licensing income of more than $600,000.